AIM ImmunoTech Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for AIM, updated each market day.
AIM AI Sentiment
AI predicts AIM ImmunoTech Inc. stock is likely to increase over the next 10 market days.
Prediction date: Sept. 21, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Sector
Exchange
Market Cap
$8,513,564
Cap Tier
Employees
21
Headquarters
OCALA, FL
Listed Since
Nov. 2, 1995
Website
AIM Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AIM Volatility
AIM ImmunoTech Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
